feed,title,long_url,short_url
Benzinga,Synaptogenix Shares Nosedive After Mid-Stage Alzheimer's Study Fails On Primary Endpoint,https://benzinga.com/general/biotech/22/12/30110823/synaptogenix-shares-nosedive-after-mid-stage-alzheimers-study-fails-on-primary-endpoint,https://da.gd/IijaF
